American Century Companies Inc. Has $101,000 Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF)

American Century Companies Inc. raised its position in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) by 98.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,360 shares of the company’s stock after purchasing an additional 22,536 shares during the period. American Century Companies Inc. owned approximately 0.10% of Cardiff Oncology worth $101,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of Cardiff Oncology by 0.5% in the first quarter. Vanguard Group Inc. now owns 1,921,257 shares of the company’s stock worth $10,260,000 after purchasing an additional 9,468 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in Cardiff Oncology by 380.6% during the second quarter. Assenagon Asset Management S.A. now owns 1,215,922 shares of the company’s stock valued at $2,699,000 after purchasing an additional 962,940 shares during the period. Blair William & Co. IL raised its stake in Cardiff Oncology by 32.4% in the 1st quarter. Blair William & Co. IL now owns 172,180 shares of the company’s stock valued at $919,000 after acquiring an additional 42,180 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of Cardiff Oncology during the second quarter worth $256,000. Finally, Rhumbline Advisers purchased a new position in Cardiff Oncology during the 2nd quarter valued at about $102,000. 16.29% of the stock is owned by institutional investors and hedge funds.

Cardiff Oncology Price Performance

CRDF opened at $2.60 on Friday. The firm has a market cap of $116.29 million, a price-to-earnings ratio of -2.89 and a beta of 1.96. Cardiff Oncology, Inc. has a 1 year low of $0.94 and a 1 year high of $6.42. The stock’s 50 day simple moving average is $2.39 and its 200 day simple moving average is $3.17.

Cardiff Oncology (NASDAQ:CRDF) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.01). Cardiff Oncology had a negative return on equity of 62.65% and a negative net margin of 6,143.91%. The company had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.12 million. During the same quarter last year, the company posted ($0.25) earnings per share. As a group, sell-side analysts anticipate that Cardiff Oncology, Inc. will post -1 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Craig Hallum initiated coverage on Cardiff Oncology in a report on Friday, September 6th. They issued a “buy” rating and a $8.00 price target on the stock.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.